Work Experience Graduated from Peking University Health Science Center in 1991 with a medical doctorate in Internal Medicine (Endocrinology and Metabolic Diseases), and remained at Peking University Third Hospital, Department of Endocrinology after graduation. Served as a visiting researcher at the Steno Diabetes Center in Denmark for two years. Appointed as Associate Chief Physician, Associate Professor, and Master's Supervisor in 1993. Appointed as Chief Physician, Professor, and Doctoral Supervisor in 2001. Appointed as Second-Level Professor at Peking University in 2009. Served as Director of the Department of Endocrinology and Director of the Endocrine Research Laboratory at Peking University Third Hospital since 2003. Concurrently served as Director of the Department of Laboratory Medicine at Peking University Third Hospital from 2014 to 2018. Appointed as Chair of the Department of Endocrinology and Metabolism, Peking University since 2024. Led the formulation of the health industry standard of the People's Republic of China, "Diabetes Screening and Diagnosis." As lead or primary writer, formulated over 10 expert consensuses, including the "Expert Consensus on Glucose-Lowering Drug Application in Patients with Type 2 Diabetes Complicated with Atherosclerotic Cardiovascular Disease," "Expert Consensus on Combination Therapy with Oral Antidiabetic Drugs in Chinese Adults with Type 2 Diabetes," "Expert Consensus on Clinical Application of Glucose-Lowering Drugs in Chinese Adults with Type 2 Diabetes Complicated with Cardiac and Renal Diseases," "Expert Consensus on Intervention of Prediabetes in Chinese Adults," and "Chinese Expert Consensus on Sodium-Glucose Cotransporter 2 Inhibitors Combined with Insulin Therapy for Type 2 Diabetes (2023 Edition)." Participated in the formulation of over 70 guidelines or consensuses. Research Work Main research directions include basic and clinical research on diabetes, endocrine metabolism and reproductive health research, and stem cell directed differentiation research. Has successively led over 30 national and provincial/ministerial research projects, including 9 projects funded by the National Natural Science Foundation of China (7 General Projects, 1 Key Project, 1 Major Research Plan), 1 National Key Research and Development Project (as lead), 1 National Science and Technology Major Project (as project leader), 2 National 973 Program Projects (as project leader), and 1 National 863 Program Project (as project leader). In recent years, the main research projects undertaken as project or task leader are as follows: [1] National Science and Technology Major Project, Screening and Identification of Novel Islet Factors in the Development and Progression of Metabolic Diseases, 2024/08-2028/07, 2 million RMB [2] National Key Research and Development Program Project: Study on Appropriate Technologies and Efficacy Evaluation of Early Behavioral Intervention for Risk Factors of Type 2 Diabetes, High Diabetes Risk, and Gestational Diabetes, 2018.8-2020.12, 12.22 million RMB [3] National Natural Science Foundation of China Key Project: The Role and Mechanism of Dynamic Changes in Pancreatic α and β Cell Function and Phenotype in Regulating Blood Glucose Homeostasis, 2019.1-2023.12, 3.52 million RMB Awards In 2016, awarded the Third Prize of Beijing Science and Technology Progress Award; in 2015, awarded the Third Prize of Beijing Medical Science and Technology Award; in 1996, awarded the Third Prize of the National Education Commission Science and Technology Progress Award (Category A). In addition, in 2018, awarded the title of "National Famous Doctor - Outstanding Contribution Award" by the National Famous Doctor Ceremony Committee; in 2018, awarded the title of "Life Hero" in the medical and health field by Health News; in 2018, awarded the honorary title of "Model of Teacher Ethics Around Me" by Peking University Third Hospital; in 2017, awarded the Outstanding Contribution Award of the Chinese Society of Endocrinology - Kuang Ankun Award, among others. Publications Published over 400 papers in Chinese core journals. Published over 100 papers in SCI journals including JAMA, Diabetes, Diabetologia, Metabolism, and Diabetes Obesity and Metabolism. Representative publications are as follows: [1] Wang D, Wei T, Cui X, Xia L, Jiang Y, Yin D, Liao X, Li F, Li J, Wu Q, Lin X, Lang S, Le Y, Yang J, Yang J, Wei R, Hong T (Corresponding author). Fam3a-mediated prohormone convertase switch in α-cells regulates pancreatic GLP-1 production in an Nr4a2-Foxa2-dependent manner. Metabolism. 2024 Oct 1:156042. doi: 10.1016/j.metabol.2024.156042. IF = 10.8 [2] Lin XF, Cui XN, Yang J, Jiang YF, Wei TJ, Xia L, Liao XY, Li F, Wang DD, Li J, Wu Q, Yin DS, Le YY, Yang K, Wei R, Hong T (Corresponding author). SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. Acta Pharmacol Sin. 2024 Sep 18. doi: 10.1038/s41401-024-01389-3. IF = 8.2 [3] Li F, Si W, Xia L, Yin D, Wei T, Tao M, Cui X, Yang J, Hong T* (Co-corresponding author), Wei R*. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol Cancer. 2024; 23(1):90. IF = 37.3 [4] Jiang Y, Yang J, Xia L, Wei T, Cui X, Wang D, Jin Z, Lin X, Li F, Yang K, Lang S, Liu Y, Hang J, Zhang Z*, Hong T* (Co-corresponding author), Wei R*. Gut microbiota-tryptophan metabolism-GLP-1 axis participates in β-cell regeneration induced by dapagliflozin. Diabetes. 2024; 73(6):926-940. IF = 7.7 [5] Wei T, Cui X, Jiang Y, Wang K, Wang D, Li F, Lin X, Gu L, Yang K, Yang J, Hong T* (Co-corresponding author), Wei R*. Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice. Diabetes. 2023; 72(5):599-610. IF = 9.337 [6] Cui X, Feng J, Wei T, Zhang L, Lang S, Yang K, Yang J, Liu J, Sterr M, Lickert H, Wei R, Hong T (Corresponding author). Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes. Diabetologia. 2023; 66(3):535-550. IF = 10.460 [7] Cui X, Feng J, Wei T, Gu L, Wang D, Lang S, Yang K, Yang J, Yan H, Wei R, Hong T (Corresponding author). Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice. iScience. 2022; 25(7):104567. IF = 6.107 [8] Hong T, Su Q, Li X, Shan Z, Chen L, Peng Y, Chen L, Yan L, Bao Y, Lyu Z, Shi L, Wang W, Guo L, Ning G, Mu Y, Zhu D. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Diabetes Metab Res Rev. 2021; 37(4):e3416. IF = 8.128 [9] Wei R, Cui X, Feng J, Gu L, Lang S, Wei T, Yang J, Liu J, Le Y, Wang H, Yang K, Hong T (Corresponding author). Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. Metabolism. 2020; 111:154324. IF = 13.934 [10] Yang J, Xiao W, Guo L, Li Q, Zhong L, Yang J, Yang J, Gao Y, Tian Q, Hong T (Corresponding author). Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. Acta Diabetol. 2020; 57(8):991-1000. IF = 4.280 [11] Liu J, Yang K, Yang J, Xiao W, Le Y, Yu F, Gu L, Lang S, Tian Q, Jin T, Wei R, Hong T (Corresponding author). Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. EBioMedicine. 2019; 41:73-84. IF = 11.205 [12] Si W, Liu X, Wei R, Zhang Y, Zhao Y, Cui L, Hong T (Corresponding author). MTA2-mediated inhibition